S’pore biotech start-up Mirxes refiles for Hong Kong IPO, eyes growth in China
SINGAPORE – Local biotech firm Mirxes has refiled its draft prospectus for an initial public offering (IPO) in Hong Kong as it now weighs a listing within 2024. The start-up, last valued at US$600 million (S$810 million), is seeking to raise over US$100 …